11月13-17日，为期5天的2020美国心脏协会科学年会（AHA 2020）虚拟会议将在线上举行。本届AHA2020年会共设立了9个Late Breaking Science（LBS）专场，包括35项LBS研究，一起先睹为快吧！
LBS.01 – 心力衰竭和房颤：维生素、矿物质、营养素等
时间：11月13日，10:30 AM - 11:30 AM
研究1：Omecamtiv Mecarbil In Chronic Heart Failure With Reduced Ejection Fraction: The Global Approach To Lowering Adverse Cardiac Outcomes Through Improving Contractility In Heart Failure (GALACTIC-HF) Trial
GALACTIC-HF研究：Omecamtiv Mecarbil治疗射血分数降低的
研究2：Ferric Carboxymaltose In Iron Deficient Patients Admitted For Acute Heart Failure
AFFIRM-AHF研究：羧基麦芽糖铁用于治疗因
研究3：The Vital Rhythm Trial: Omega-3 Fatty Acid And Vitamin D Supplementation In The Primary Prevention Of Atrial Fibrillation
Vital Rhythm研究：使用Omega-3脂肪酸和
LBS.02 – 弯曲的心血管疾病曲线——精准还是复方制剂？
时间：11月13日，12:00 PM - 1:00 PM
研究1：A Polypill For Primary Prevention Of Cardiovascular Disease In Intermediate Risk People: Results Of The International Polycap Study (TIPS)-3
TIPS-3研究：一种用于中危心血管疾病患者一级预防的复方制剂
研究2：Aspirin Alone And In Combination With A Polypill In Cardiovascular Disease Primary Prevention: Results From The International Polycap Study (TIPS)-3
TIPS-3研究：
研究3：Prevalence And Prediction Of Coronary Artery Disease In The General Population- Results From The Swedish Cardiopulmonary Bioimage Study (scapis)
SCAPIS研究：普通人群冠状动脉疾病的患病率和预测
LBS.03 – 目前冠心病和瓣膜疾病面临的挑战
时间：11月14日，12:00 PM - 1:00 PM
研究1：Ticagrelor Versus Clopidogrel In Elective Percutaneous Coronary Intervention : The Alpheus Trial
ALPHEUS研究：在进行择期经皮冠脉介入治疗的患者中，对比
研究2：Coronary Oct And Cardiac Mri To Determine Underlying Causes Of Minoca In Women
HARP-MINOCA研究：使用冠脉OCT和心脏MRI诊断女性冠状动脉非阻塞型心肌梗死（MINOCA）的潜在病因
研究3：Oral Anti-xa Anticoagulation After Trans-aortic Valve Implantation For Aortic Stenosis: The Randomized Atlantis Trial
Atlantis研究：在经主动脉瓣植入术后口服抗Xa因子抗凝药物进行治疗
LBS.04 – 脂质管理中的鱼油、花式药物及挫折感
时间：11月15日，9:00 AM - 10:00 AM
研究1：STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) In Patients With High Vascular Risk And Atherogenic Dyslipidemia
STRENGTH研究：在高血管风险和致动脉粥样硬化血脂异常患者中，应用Omega-3羧酸（Epanova）的心血管结局
研究2：Effects Of N-3 Fatty Acid Supplements On Clinical Outcome After Myocardial Infarction In The Elderly: Results Of The Omemi Trial
OMEMI研究：N-3脂肪酸补充剂对老年患者心肌梗死后临床结局的影响
研究3：A Three-arm N-of-1 Trial With Statin, Placebo And Tablet Free Periods, To Verify Side Effects And Identify Their Cause: The SAMSON Trial
SAMSON研究：他汀类药物、安慰剂和无片剂期的三臂单病例随机对照试验（N-of-1 trial），以验证不良反应并确定其原因
研究4：The Efficacy And Safety Of Evinacumab In Patients With Refractory Hypercholesterolemia
Evinacumab在难治性高胆固醇血症患者中的疗效和安全性
LBS.05 - 支架、瓣膜和血栓
时间：11月15日，7:30 PM - 8:30 PM
研究1：A Prospective Multicenter Randomized Controlled Trial Assessing The Safety And Efficacy Of The BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System In Patients With Stable Or Non-ST Elevation Acute Coronary Syndromes: Primary Endpoint Results Of The PIONEER III Trial
PIONEER Ⅲ研究的主要终点结果：评估BuMA Supreme™生物可降解药物涂层冠脉支架系统在稳定或非ST段抬高型急性冠脉综合征患者中安全性和有效性的前瞻性多中心随机对照试验
研究2：One Month Dual Antipletelet Therapy Followed By Aspirin Monotherapy After Drug Eluting Stent Implantation
One-Month DAPT研究：在植入药物洗脱支架后1个月内进行双联抗血小板治疗，之后进行阿司匹林单药治疗的疗效
研究3：Rivaroxaban Versus Warfarin In Patients With Bioprosthetic Mitral Valves And Atrial Fibrillation Or Flutter: Primary Results From The RIVER Randomized Trial
RIVER研究的初步结果：在植入人工二尖瓣的房颤/房扑患者中比较
LBS.06 –筛查还是不筛查？之后是什么？房颤的检测与治疗研究
时间：11月16日，9:00 AM - 10:00 AM
研究1：Enhanced Monitoring For Atrial Fibrillation Following Cardiac Surgery: Primary Results Of The SEARCH-AF Cardiolink Randomized Trial
SEARCH-AF Cardiolink随机试验的初步结果：心脏手术后强化房颤监测
研究2：Screening For Atrial Fibrillation In Older Adults At Primary Care Visits Using Single Lead Electrocardiograms: The VITAL-AF Trial
VITAL-AF研究：在初级保健门诊使用单导联
研究3：3-year Clinical Outcomes In A Nationwide, Randomized, Pragmatic Clinical Trial Of Atrial Fibrillation Screening - Mhealth Screening To Prevent Strokes (mstops)
MSTOPS研究：全国性、随机、实用的房颤筛查临床试验的3年临床结果（预防卒中的Mhealth筛查）
研究4：Early Invasive Intervention For Atrial Fibrillation
EARLY-AF研究：房颤的早期介入治疗
LBS.07 – 脑、肾和心脏的随机试验
时间：11月16日， 7:10 PM - 8:30 PM
研究1：Finerenone And Cardiovascular Outcomes In Patients With Chronic Kidney Disease And Type 2 Diabetes
FIDELIO-DKD研究：在慢性肾脏病合并2型糖尿病患者中，应用
研究2：Ticagrelor Added To Aspirin In Acute Ischemic Stroke Or Tia Of Atherosclerotic Origin
THALES研究：在阿司匹林基础上加用替格瑞洛，以治疗源于动脉粥样硬化的急性缺血性卒中或
研究3：RHAPSODY: Rilonacept An IL-1α And IL-1β Trap Resolves Pericarditis Episodes And Reduces Risk Of Recurrence In A Phase 3 Trial Of Patients With Recurrent Pericarditis
RHAPSODY研究：心包炎复发患者的3期临床试验显示，Rilonacept作为IL-1α 和 IL-1β Trap可降低心包炎发作及复发风险
研究4：Rapid Assessment Of Potential Ischaemic Heart Disease With Ctca: The Rapid-ctca Trial. A Randomised Trial Of Ctcain The Evaluation, Intervention And Outcome Of adults With Suspected or Confirmed Acute Coronary Syndrome Presenting To The Emergency Department
RAPID-CTCA研究： CTCA用于急诊、可疑或确诊急性冠脉综合征成人患者的缺血性心脏病的评估、干预和预后
研究5：SOLOIST-WHF: Sotagliflozin in Diabetes Patients with Recent Worsening Heart Failure
SOLOIST-WHF研究：索格列净在近期心力衰竭恶化的糖尿病患者中的疗效
研究6：SCORED: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
SCORED研究：索格列净在糖尿病合并慢性肾病患者中的疗效
LBS.08 –AHA热点：COVID-19、流感疫苗和心血管疾病
时间：11月17日，9:00 AM - 10:00 AM
研究1：The AHA COVID-19 Cardiovascular Disease Registry: Design, Implementation, and Initial Results
AHA COVID-19心血管疾病注册研究：设计、实施和初步结果
研究2：Racial and Ethnic Differences in Treatment and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association COVID-19 Cardiovascular Disease Registry
AHA COVID-19心血管疾病注册研究：COVID-19住院患者在治疗和结局方面的种族差异
研究3：Association of Body Mass Index with Death, Mechanical Ventilation, and Cardiovascular Outcomes in COVID-19: Findings from the AHA COVID-19 Cardiovascular Disease Registry
AHA COVID-19心血管疾病注册研究：在COVID-19患者中，
研究4：Impact Of Cardiovascular Disease On Outcomes Among Hospitalized COVID-19 Patients: Results From >14,000 Patients Across The United States
全美＞14000例患者的结果：心血管疾病对住院COVID-19患者结局的影响
研究5：High Dose Versus Standard Dose Influenza Vaccine In Patients With High Risk Cardiovascular Disease: Results From The Invested Trial
INVESTED研究：在高危心血管疾病患者中，高剂量与标准剂量流感疫苗的对比
LBS.09 –高科技或高触感：优化患者护理的创新策略
时间：11月17日，12:00 PM - 1:00 PM
研究1：An Electronically Delivered, Patient-activation Tool For Intensification Of Medications For Chronic Heart Failure With Reduced Ejection Fraction: The EPIC-HF Trial
EPIC-HF研究：一种用于强化射血分数降低的慢性心力衰竭药物治疗的电子传递、患者激活工具
研究2：My Recorded On-demand Audio Discharge Instructions(MyRoad) In Heart Failure
MYROAD研究：录制的点播音频放电说明（MyRoad）在心力衰竭中的应用
研究3：Digital Care Transformation: One-year Report Of >5,000 Patients Enrolled An A Remote Algorithm-based Cv Risk Management Program To Achieve Optimal Lipid And Hypertension Control
数字化医疗转型：在＞5000例患者中，报告了基于远程算法的心血管风险管理程序（实现最佳的脂质和高血压控制）的1年报告
研究4：Group Medical Visits And Microfinance For Patients With Diabetes And Hypertension In Western Kenya: Results Of The BIGPIC Trial
BIGPIC研究：肯尼亚西部地区，糖尿病合并高血压患者的团体医疗访问和小额信贷
(本网站所有内容，凡注明来源为“医脉通”，版权均归医脉通所有，未经授权，任何媒体、网站或个人不得转载，否则将追究法律责任，授权转载时须注明“来源：医脉通”。本网注明来源为其他媒体的内容为转载，转载仅作观点分享，版权归原作者所有，如有侵犯版权，请及时联系我们。)
